Current immunotherapy treatments like pembrolizumab have provided promising results for metastatic Colorectal Cancer Patients who have high microsatellite instability or are mismatch repair deficient. Unfortunately, this consists of only ~5% of the total colorectal cancer sub-population and the majority remain non-responsive to immunotherapy. Based on previously established pre-clinical results, scientists are now exploring combinations of […]

The post PDL1-MEK inhibitor combination for microsatellite-stable Metastatic Colorectal Cancer patients appeared first on Innoplexus.